+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pembrolizumab"

Thyroid Cancer Drugs Market Report 2026 - Product Thumbnail Image

Thyroid Cancer Drugs Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
MSI-H and dMMR Market Report 2026 - Product Thumbnail Image

MSI-H and dMMR Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Hepatocellular Carcinoma Drugs Market Report 2026 - Product Thumbnail Image

Hepatocellular Carcinoma Drugs Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
Urothelial Cancer Drugs Market Report 2026 - Product Thumbnail Image

Urothelial Cancer Drugs Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
Checkpoint Inhibitor Refractory Cancer Market Report 2026 - Product Thumbnail Image

Checkpoint Inhibitor Refractory Cancer Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Drugs for Immunotherapy Market Report 2026 - Product Thumbnail Image

Drugs for Immunotherapy Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Oral Cancer Treatment Market Report 2026 - Product Thumbnail Image

Oral Cancer Treatment Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Laryngeal Cancer Therapeutics Market Report 2026 - Product Thumbnail Image

Laryngeal Cancer Therapeutics Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2026 - Product Thumbnail Image

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Bispecific Antibodies - Competitive Landscape, 2026 - Product Thumbnail Image

Bispecific Antibodies - Competitive Landscape, 2026

  • Report
  • January 2026
  • 450 Pages
  • Global
From
Antibody Drug Conjugates - Competitive Landscape, 2026 - Product Thumbnail Image

Antibody Drug Conjugates - Competitive Landscape, 2026

  • Report
  • January 2026
  • 450 Pages
  • Global
From
From
From
From
From
Ewing Sarcoma - Pipeline Insight, 2025 - Product Thumbnail Image

Ewing Sarcoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 115 Pages
  • Global
From
Malignant Pleural Mesothelioma- Pipeline Insight, 2025 - Product Thumbnail Image

Malignant Pleural Mesothelioma- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
4-1BB Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

4-1BB Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 100 Pages
  • Global
From
Loading Indicator

Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers. Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated. Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more